What is the your choice of treatment after progression or AE following pembrolizumab in metastatic melanoma?
Patient does not have BRAF mutation.
Answer from: Medical Oncologist at Academic Institution
There is unfortunately limited prospective randomized data to guide us after progression due to anti-PD-1 therapy in metastatic melanoma. There is little benefit to re-challenging with the other anti-PD1 therapy (pembro or nivo after nivo or pembro etc) and dependent on AE would most likely not...
Sign in or Register to read more